The preclinical evidence highlighting the potential synergy between mitogen-activated protein kinase pathway inhibition via MEK inhibitors and the heightened anti-tumour activity of PD-1 inhibitors due to increased MHC-1 and PD-L1 expression has sparked interest in their combined use [52]. The gene discussed is CD274; the disease is neoplasm.